Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1999 Feb;107(Suppl 1):37–47. doi: 10.1289/ehp.99107s137

Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.

A Hirvonen 1
PMCID: PMC1566364  PMID: 10229705

Abstract

The variation in individual responses to exogenous agents is exceptionally wide. It is because of this large diversity of responsiveness that risk factors to environmentally induced diseases have been difficult to pinpoint, particularly at low exposure levels. Opportunities now exist for studies of host factors in cancer or other diseases in which an environmental component can be presumed. Many of the studies have shown an elevated disease proneness for individuals carrying the potential at-risk alleles of metabolic genes, but a number of controversial results have also been reported. This article is an overview of the data published to date on metabolic genotypes related to individual susceptibility to cancer.

Full text

PDF
37

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agúndez J. A., Ledesma M. C., Ladero J. M., Benítez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther. 1995 Mar;57(3):265–269. doi: 10.1016/0009-9236(95)90151-5. [DOI] [PubMed] [Google Scholar]
  2. Agúndez J. A., Olivera M., Martínez C., Ladero J. M., Benítez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics. 1996 Oct;6(5):423–428. [PubMed] [Google Scholar]
  3. Aklillu E., Persson I., Bertilsson L., Johansson I., Rodrigues F., Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996 Jul;278(1):441–446. [PubMed] [Google Scholar]
  4. Alexandrie A. K., Sundberg M. I., Seidegård J., Tornling G., Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994 Sep;15(9):1785–1790. doi: 10.1093/carcin/15.9.1785. [DOI] [PubMed] [Google Scholar]
  5. Ali-Osman F., Akande O., Antoun G., Mao J. X., Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997 Apr 11;272(15):10004–10012. doi: 10.1074/jbc.272.15.10004. [DOI] [PubMed] [Google Scholar]
  6. Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Michalek A. M., Laughlin R., Nemoto T., Gillenwater K. A. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 1996 Nov 13;276(18):1494–1501. [PubMed] [Google Scholar]
  7. Anttila S., Hirvonen A., Vainio H., Husgafvel-Pursiainen K., Hayes J. D., Ketterer B. Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res. 1993 Dec 1;53(23):5643–5648. [PubMed] [Google Scholar]
  8. Anttila S., Luostarinen L., Hirvonen A., Elovaara E., Karjalainen A., Nurminen T., Hayes J. D., Vainio H., Ketterer B. Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. Cancer Res. 1995 Aug 1;55(15):3305–3309. [PubMed] [Google Scholar]
  9. Babu S. R., Lakshmi V. M., Owens I. S., Zenser T. V., Davis B. B. Human liver glucuronidation of benzidine. Carcinogenesis. 1994 Sep;15(9):2003–2007. doi: 10.1093/carcin/15.9.2003. [DOI] [PubMed] [Google Scholar]
  10. Badawi A. F., Hirvonen A., Bell D. A., Lang N. P., Kadlubar F. F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 1995 Nov 15;55(22):5230–5237. [PubMed] [Google Scholar]
  11. Barrett J. C. Mechanisms for species differences in receptor-mediated carcinogenesis. Mutat Res. 1995 Dec;333(1-2):189–202. doi: 10.1016/0027-5107(95)00145-x. [DOI] [PubMed] [Google Scholar]
  12. Bartsch H., Rojas M., Alexandrov K., Camus A. M., Castegnaro M., Malaveille C., Anttila S., Hirvonen K., Husgafvel-Pursiainen K., Hietanen E. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. Pharmacogenetics. 1995;5(Spec No):S84–S90. doi: 10.1097/00008571-199512001-00007. [DOI] [PubMed] [Google Scholar]
  13. Bell D. A., Badawi A. F., Lang N. P., Ilett K. F., Kadlubar F. F., Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 1995 Nov 15;55(22):5226–5229. [PubMed] [Google Scholar]
  14. Bell D. A., Stephens E. A., Castranio T., Umbach D. M., Watson M., Deakin M., Elder J., Hendrickse C., Duncan H., Strange R. C. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995 Aug 15;55(16):3537–3542. [PubMed] [Google Scholar]
  15. Blum M., Grant D. M., McBride W., Heim M., Meyer U. A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990 Apr;9(3):193–203. doi: 10.1089/dna.1990.9.193. [DOI] [PubMed] [Google Scholar]
  16. Bouchardy C., Benhamou S., Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res. 1996 Jan 15;56(2):251–253. [PubMed] [Google Scholar]
  17. Bouchardy C., Mitrunen K., Wikman H., Husgafvel-Pursiainen K., Dayer P., Benhamou S., Hirvonen A. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics. 1998 Aug;8(4):291–298. doi: 10.1097/00008571-199808000-00002. [DOI] [PubMed] [Google Scholar]
  18. Brockmöller J., Kerb R., Drakoulis N., Staffeldt B., Roots I. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res. 1994 Aug 1;54(15):4103–4111. [PubMed] [Google Scholar]
  19. Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U. A. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991 Oct;10(8):545–558. doi: 10.1089/dna.1991.10.545. [DOI] [PubMed] [Google Scholar]
  20. Butler M. A., Lang N. P., Young J. F., Caporaso N. E., Vineis P., Hayes R. B., Teitel C. H., Massengill J. P., Lawsen M. F., Kadlubar F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992 Jun;2(3):116–127. doi: 10.1097/00008571-199206000-00003. [DOI] [PubMed] [Google Scholar]
  21. Carriere V., Goasduff T., Ratanasavanh D., Morel F., Gautier J. C., Guillouzo A., Beaune P., Berthou F. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol. 1993 Nov-Dec;6(6):852–857. doi: 10.1021/tx00036a015. [DOI] [PubMed] [Google Scholar]
  22. Carrière V., Berthou F., Baird S., Belloc C., Beaune P., de Waziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics. 1996 Jun;6(3):203–211. doi: 10.1097/00008571-199606000-00002. [DOI] [PubMed] [Google Scholar]
  23. Cascorbi I., Brockmöller J., Mrozikiewicz P. M., Bauer S., Loddenkemper R., Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res. 1996 Sep 1;56(17):3961–3966. [PubMed] [Google Scholar]
  24. Cascorbi I., Brockmöller J., Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 1996 Nov 1;56(21):4965–4969. [PubMed] [Google Scholar]
  25. Cascorbi I., Drakoulis N., Brockmöller J., Maurer A., Sperling K., Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995 Sep;57(3):581–592. [PMC free article] [PubMed] [Google Scholar]
  26. Chen J., Stampfer M. J., Hough H. L., Garcia-Closas M., Willett W. C., Hennekens C. H., Kelsey K. T., Hunter D. J. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res. 1998 Aug 1;58(15):3307–3311. [PubMed] [Google Scholar]
  27. Cholerton S., Idle M. E., Vas A., Gonzalez F. J., Idle J. R. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J Chromatogr. 1992 Mar 27;575(2):325–330. doi: 10.1016/0378-4347(92)80166-n. [DOI] [PubMed] [Google Scholar]
  28. Coles B., Ketterer B. The role of glutathione and glutathione transferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol. 1990;25(1):47–70. doi: 10.3109/10409239009090605. [DOI] [PubMed] [Google Scholar]
  29. Costa M. Model for the epigenetic mechanism of action of nongenotoxic carcinogens. Am J Clin Nutr. 1995 Mar;61(3 Suppl):666S–669S. doi: 10.1093/ajcn/61.3.666S. [DOI] [PubMed] [Google Scholar]
  30. Crofts F., Taioli E., Trachman J., Cosma G. N., Currie D., Toniolo P., Garte S. J. Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 1994 Dec;15(12):2961–2963. doi: 10.1093/carcin/15.12.2961. [DOI] [PubMed] [Google Scholar]
  31. Dahl M. L., Johansson I., Bertilsson L., Ingelman-Sundberg M., Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995 Jul;274(1):516–520. [PubMed] [Google Scholar]
  32. Daly A. K., Armstrong M., Monkman S. C., Idle M. E., Idle J. R. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics. 1991 Oct;1(1):33–41. doi: 10.1097/00008571-199110000-00006. [DOI] [PubMed] [Google Scholar]
  33. Daly A. K., Brockmöller J., Broly F., Eichelbaum M., Evans W. E., Gonzalez F. J., Huang J. D., Idle J. R., Ingelman-Sundberg M., Ishizaki T. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 1996 Jun;6(3):193–201. doi: 10.1097/00008571-199606000-00001. [DOI] [PubMed] [Google Scholar]
  34. Deakin M., Elder J., Hendrickse C., Peckham D., Baldwin D., Pantin C., Wild N., Leopard P., Bell D. A., Jones P. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis. 1996 Apr;17(4):881–884. doi: 10.1093/carcin/17.4.881. [DOI] [PubMed] [Google Scholar]
  35. Deitz A. C., Doll M. A., Hein D. W. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem. 1997 Nov 15;253(2):219–224. doi: 10.1006/abio.1997.2379. [DOI] [PubMed] [Google Scholar]
  36. Doll M. A., Jiang W., Deitz A. C., Rustan T. D., Hein D. W. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun. 1997 Apr 28;233(3):584–591. doi: 10.1006/bbrc.1997.6501. [DOI] [PubMed] [Google Scholar]
  37. Eaton D. L., Gallagher E. P., Bammler T. K., Kunze K. L. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 1995 Oct;5(5):259–274. doi: 10.1097/00008571-199510000-00001. [DOI] [PubMed] [Google Scholar]
  38. Eaton D. L., Gallagher E. P., Bammler T. K., Kunze K. L. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 1995 Oct;5(5):259–274. doi: 10.1097/00008571-199510000-00001. [DOI] [PubMed] [Google Scholar]
  39. Eickelmann P., Schulz W. A., Rohde D., Schmitz-Dräger B., Sies H. Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe Seyler. 1994 Jul;375(7):439–445. doi: 10.1515/bchm3.1994.375.7.439. [DOI] [PubMed] [Google Scholar]
  40. Esteller M., Garcia A., Martinez-Palones J. M., Xercavins J., Reventos J. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis. 1997 Dec;18(12):2307–2311. doi: 10.1093/carcin/18.12.2307. [DOI] [PubMed] [Google Scholar]
  41. Etter H. U., Richter C., Ohta Y., Winterhalter K. H., Sasabe H., Kawato S. Rotation and interaction with epoxide hydrase of cytochrome P-450 in proteoliposomes. J Biol Chem. 1991 Oct 5;266(28):18600–18605. [PubMed] [Google Scholar]
  42. Evans D. A., Eze L. C., Whibley E. J. The association of the slow acetylator phenotype with bladder cancer. J Med Genet. 1983 Oct;20(5):330–333. doi: 10.1136/jmg.20.5.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Fernandez-Salguero P., Gonzalez F. J. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics. 1995;5(Spec No):S123–S128. doi: 10.1097/00008571-199512001-00013. [DOI] [PubMed] [Google Scholar]
  44. Fernandez-Salguero P., Hoffman S. M., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J. D., Evans W. E., Idle J. R. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet. 1995 Sep;57(3):651–660. [PMC free article] [PubMed] [Google Scholar]
  45. Frederickson S. M., Messing E. M., Reznikoff C. A., Swaminathan S. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):25–32. [PubMed] [Google Scholar]
  46. Fujii-Kuriyama Y., Ema M., Mimura J., Sogawa K. Ah receptor: a novel ligand-activated transcription factor. Exp Clin Immunogenet. 1994;11(2-3):65–74. doi: 10.1159/000424195. [DOI] [PubMed] [Google Scholar]
  47. Furlong C. E., Costa L. G., Hassett C., Richter R. J., Sundstrom J. A., Adler D. A., Disteche C. M., Omiecinski C. J., Chapline C., Crabb J. W. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact. 1993 Jun;87(1-3):35–48. doi: 10.1016/0009-2797(93)90023-r. [DOI] [PubMed] [Google Scholar]
  48. Giovannucci E., Rimm E. B., Stampfer M. J., Colditz G. A., Ascherio A., Kearney J., Willett W. C. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J Natl Cancer Inst. 1994 Feb 2;86(3):183–191. doi: 10.1093/jnci/86.3.183. [DOI] [PubMed] [Google Scholar]
  49. Giovannucci E., Willett W. C. Dietary factors and risk of colon cancer. Ann Med. 1994 Dec;26(6):443–452. doi: 10.3109/07853899409148367. [DOI] [PubMed] [Google Scholar]
  50. Goldstein J. A., Ishizaki T., Chiba K., de Morais S. M., Bell D., Krahn P. M., Evans D. A. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997 Feb;7(1):59–64. doi: 10.1097/00008571-199702000-00008. [DOI] [PubMed] [Google Scholar]
  51. Golka K., Prior V., Blaszkewicz M., Cascorbi I., Schöps W., Kierfeld G., Roots I., Bolt H. M. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health. 1996 Oct;22(5):332–338. doi: 10.5271/sjweh.150. [DOI] [PubMed] [Google Scholar]
  52. Gonzalez F. J., Aoyama T., Gelboin H. V. Activation of promutagens by human cDNA-expressed cytochrome P450s. Prog Clin Biol Res. 1990;340B:77–86. [PubMed] [Google Scholar]
  53. Gonzalez F. J. Genetic polymorphism and cancer susceptibility: fourteenth Sapporo Cancer Seminar. Cancer Res. 1995 Feb 1;55(3):710–715. [PubMed] [Google Scholar]
  54. Grant D. M., Blum M., Beer M., Meyer U. A. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol. 1991 Feb;39(2):184–191. [PubMed] [Google Scholar]
  55. Grant D. M., Hughes N. C., Janezic S. A., Goodfellow G. H., Chen H. J., Gaedigk A., Yu V. L., Grewal R. Human acetyltransferase polymorphisms. Mutat Res. 1997 May 12;376(1-2):61–70. doi: 10.1016/s0027-5107(97)00026-2. [DOI] [PubMed] [Google Scholar]
  56. Guengerich F. P. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett. 1994 Feb 1;70(2):133–138. doi: 10.1016/0378-4274(94)90156-2. [DOI] [PubMed] [Google Scholar]
  57. Guengerich F. P., Kim D. H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol. 1991 Mar-Apr;4(2):168–179. doi: 10.1021/tx00020a008. [DOI] [PubMed] [Google Scholar]
  58. Harries L. W., Stubbins M. J., Forman D., Howard G. C., Wolf C. R. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997 Apr;18(4):641–644. doi: 10.1093/carcin/18.4.641. [DOI] [PubMed] [Google Scholar]
  59. Harris M. J., Coggan M., Langton L., Wilson S. R., Board P. G. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics. 1998 Feb;8(1):27–31. doi: 10.1097/00008571-199802000-00004. [DOI] [PubMed] [Google Scholar]
  60. Hassett C., Aicher L., Sidhu J. S., Omiecinski C. J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet. 1994 Mar;3(3):421–428. doi: 10.1093/hmg/3.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Hassett C., Robinson K. B., Beck N. B., Omiecinski C. J. The human microsomal epoxide hydrolase gene (EPHX1): complete nucleotide sequence and structural characterization. Genomics. 1994 Sep 15;23(2):433–442. doi: 10.1006/geno.1994.1520. [DOI] [PubMed] [Google Scholar]
  62. Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem. 1991 Oct;110(4):559–565. doi: 10.1093/oxfordjournals.jbchem.a123619. [DOI] [PubMed] [Google Scholar]
  63. Hayashi S., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem. 1991 Sep;110(3):407–411. doi: 10.1093/oxfordjournals.jbchem.a123594. [DOI] [PubMed] [Google Scholar]
  64. Hayes J. D., Pulford D. J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30(6):445–600. doi: 10.3109/10409239509083491. [DOI] [PubMed] [Google Scholar]
  65. Hearse D. J., Weber W. W. Multiple N-acetyltransferases and drug metabolism. Tissue distribution, characterization and significance of mammalian N-acetyltransferase. Biochem J. 1973 Mar;132(3):519–526. doi: 10.1042/bj1320519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Hein D. W., Doll M. A., Rustan T. D., Gray K., Feng Y., Ferguson R. J., Grant D. M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993 Aug;14(8):1633–1638. doi: 10.1093/carcin/14.8.1633. [DOI] [PubMed] [Google Scholar]
  67. Hein D. W., Rustan T. D., Doll M. A., Bucher K. D., Ferguson R. J., Feng Y., Furman E. J., Gray K. Acetyltransferases and susceptibility to chemicals. Toxicol Lett. 1992 Dec;64-65 Spec No:123–130. doi: 10.1016/0378-4274(92)90181-i. [DOI] [PubMed] [Google Scholar]
  68. Hennings H., Glick A. B., Greenhalgh D. A., Morgan D. L., Strickland J. E., Tennenbaum T., Yuspa S. H. Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med. 1993 Jan;202(1):1–8. doi: 10.3181/00379727-202-43511a. [DOI] [PubMed] [Google Scholar]
  69. Hildesheim A., Anderson L. M., Chen C. J., Cheng Y. J., Brinton L. A., Daly A. K., Reed C. D., Chen I. H., Caporaso N. E., Hsu M. M. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 1997 Aug 20;89(16):1207–1212. doi: 10.1093/jnci/89.16.1207. [DOI] [PubMed] [Google Scholar]
  70. Hines R. N., Cashman J. R., Philpot R. M., Williams D. E., Ziegler D. M. The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression. Toxicol Appl Pharmacol. 1994 Mar;125(1):1–6. doi: 10.1006/taap.1994.1042. [DOI] [PubMed] [Google Scholar]
  71. Hirvonen A. Combinations of susceptible genotypes and individual responses to toxicants. Environ Health Perspect. 1997 Jun;105 (Suppl 4):755–758. doi: 10.1289/ehp.97105s4755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis. 1993 Jan;14(1):85–88. doi: 10.1093/carcin/14.1.85. [DOI] [PubMed] [Google Scholar]
  73. Hirvonen A., Husgafvel-Pursiainen K., Karjalainen A., Anttila S., Vainio H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):485–489. [PubMed] [Google Scholar]
  74. Hirvonen A., Pelin K., Tammilehto L., Karjalainen A., Mattson K., Linnainmaa K. Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res. 1995 Jul 15;55(14):2981–2983. [PubMed] [Google Scholar]
  75. Hirvonen A., Saarikoski S. T., Linnainmaa K., Koskinen K., Husgafvel-Pursiainen K., Mattson K., Vainio H. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst. 1996 Dec 18;88(24):1853–1856. doi: 10.1093/jnci/88.24.1853. [DOI] [PubMed] [Google Scholar]
  76. Hu X., O'Donnell R., Srivastava S. K., Xia H., Zimniak P., Nanduri B., Bleicher R. J., Awasthi S., Awasthi Y. C., Ji X. Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7beta,8alpha-dihydroxy-9alpha,10alpha-ox y-7,8,9,10-tetrahydrobenzo(a)pyrene. Biochem Biophys Res Commun. 1997 Jun 18;235(2):424–428. doi: 10.1006/bbrc.1997.6777. [DOI] [PubMed] [Google Scholar]
  77. Humbert R., Adler D. A., Disteche C. M., Hassett C., Omiecinski C. J., Furlong C. E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993 Jan;3(1):73–76. doi: 10.1038/ng0193-73. [DOI] [PubMed] [Google Scholar]
  78. Hunninghake G. W., Crystal R. G. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis. 1983 Nov;128(5):833–838. doi: 10.1164/arrd.1983.128.5.833. [DOI] [PubMed] [Google Scholar]
  79. Hunter D. J., Hankinson S. E., Hough H., Gertig D. M., Garcia-Closas M., Spiegelman D., Manson J. E., Colditz G. A., Willett W. C., Speizer F. E. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis. 1997 Nov;18(11):2127–2132. doi: 10.1093/carcin/18.11.2127. [DOI] [PubMed] [Google Scholar]
  80. Ikeya K., Jaiswal A. K., Owens R. A., Jones J. E., Nebert D. W., Kimura S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol. 1989 Sep;3(9):1399–1408. doi: 10.1210/mend-3-9-1399. [DOI] [PubMed] [Google Scholar]
  81. Ilett K. F., Castleden W. M., Vandongen Y. K., Stacey M. C., Butler M. A., Kadlubar F. F. Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease. Clin Pharmacol Ther. 1993 Sep;54(3):317–322. doi: 10.1038/clpt.1993.153. [DOI] [PubMed] [Google Scholar]
  82. Inskip A., Elexperu-Camiruaga J., Buxton N., Dias P. S., MacIntosh J., Campbell D., Jones P. W., Yengi L., Talbot J. A., Strange R. C. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Biochem J. 1995 Dec 15;312(Pt 3):713–716. doi: 10.1042/bj3120713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Ishibe N., Hankinson S. E., Colditz G. A., Spiegelman D., Willett W. C., Speizer F. E., Kelsey K. T., Hunter D. J. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res. 1998 Feb 15;58(4):667–671. [PubMed] [Google Scholar]
  84. Jackson M. A., Stack H. F., Waters M. D. The genetic toxicology of putative nongenotoxic carcinogens. Mutat Res. 1993 Mar;296(3):241–277. doi: 10.1016/0165-1110(93)90014-e. [DOI] [PubMed] [Google Scholar]
  85. Jahnke V., Matthias C., Fryer A., Strange R. Glutathione S-transferase and cytochrome-P-450 polymorphism as risk factors for squamous cell carcinoma of the larynx. Am J Surg. 1996 Dec;172(6):671–673. doi: 10.1016/s0002-9610(96)00298-x. [DOI] [PubMed] [Google Scholar]
  86. Jin C. J., Miners J. O., Burchell B., Mackenzie P. I. The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. Carcinogenesis. 1993 Dec;14(12):2637–2639. doi: 10.1093/carcin/14.12.2637. [DOI] [PubMed] [Google Scholar]
  87. Johansson I., Lundqvist E., Bertilsson L., Dahl M. L., Sjöqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11825–11829. doi: 10.1073/pnas.90.24.11825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Johansson I., Oscarson M., Yue Q. Y., Bertilsson L., Sjöqvist F., Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994 Sep;46(3):452–459. [PubMed] [Google Scholar]
  89. Joseph P., Xie T., Xu Y., Jaiswal A. K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res. 1994;6(10-11):525–532. [PubMed] [Google Scholar]
  90. Jourenkova N., Reinikainen M., Bouchardy C., Dayer P., Benhamou S., Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):19–23. [PubMed] [Google Scholar]
  91. Kadlubar F. F., Butler M. A., Kaderlik K. R., Chou H. C., Lang N. P. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect. 1992 Nov;98:69–74. doi: 10.1289/ehp.929869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther. 1993 Sep;54(3):235–241. doi: 10.1038/clpt.1993.142. [DOI] [PubMed] [Google Scholar]
  93. Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993 Feb;14(1):77–87. doi: 10.1016/1040-8428(93)90007-q. [DOI] [PubMed] [Google Scholar]
  94. Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990 Apr 9;263(1):131–133. doi: 10.1016/0014-5793(90)80721-t. [DOI] [PubMed] [Google Scholar]
  95. Kellermann G., Shaw C. R., Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med. 1973 Nov 1;289(18):934–937. doi: 10.1056/NEJM197311012891802. [DOI] [PubMed] [Google Scholar]
  96. Kim R. B., O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther. 1995 Jun;57(6):645–655. doi: 10.1016/0009-9236(95)90227-9. [DOI] [PubMed] [Google Scholar]
  97. Kim R. B., O'Shea D., Wilkinson G. R. Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics. 1994 Jun;4(3):162–165. [PubMed] [Google Scholar]
  98. Kinzler K. W., Vogelstein B. Life (and death) in a malignant tumour. Nature. 1996 Jan 4;379(6560):19–20. doi: 10.1038/379019a0. [DOI] [PubMed] [Google Scholar]
  99. Kolesar J. M., Kuhn J. G., Burris H. A., 3rd Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst. 1995 Jul 5;87(13):1022–1024. doi: 10.1093/jnci/87.13.1022-a. [DOI] [PubMed] [Google Scholar]
  100. Lakshmi V. M., Bell D. A., Watson M. A., Zenser T. V., Davis B. B. N-acetylbenzidine and N,N'-diacetylbenzidine formation by rat and human liver slices exposed to benzidine. Carcinogenesis. 1995 Jul;16(7):1565–1571. doi: 10.1093/carcin/16.7.1565. [DOI] [PubMed] [Google Scholar]
  101. Lancaster J. M., Brownlee H. A., Bell D. A., Futreal P. A., Marks J. R., Berchuck A., Wiseman R. W., Taylor J. A. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog. 1996 Nov;17(3):160–162. doi: 10.1002/(SICI)1098-2744(199611)17:3<160::AID-MC8>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  102. Landi M. T., Bertazzi P. A., Shields P. G., Clark G., Lucier G. W., Garte S. J., Cosma G., Caporaso N. E. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics. 1994 Oct;4(5):242–246. doi: 10.1097/00008571-199410000-00002. [DOI] [PubMed] [Google Scholar]
  103. Lin H. J., Han C. Y., Lin B. K., Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 1994 Jun;4(3):125–134. doi: 10.1097/00008571-199406000-00003. [DOI] [PubMed] [Google Scholar]
  104. Lin H. J., Han C. Y., Lin B. K., Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet. 1993 Apr;52(4):827–834. [PMC free article] [PubMed] [Google Scholar]
  105. Lind C., Cadenas E., Hochstein P., Ernster L. DT-diaphorase: purification, properties, and function. Methods Enzymol. 1990;186:287–301. doi: 10.1016/0076-6879(90)86122-c. [DOI] [PubMed] [Google Scholar]
  106. London S. J., Daly A. K., Cooper J., Navidi W. C., Carpenter C. L., Idle J. R. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst. 1995 Aug 16;87(16):1246–1253. doi: 10.1093/jnci/87.16.1246. [DOI] [PubMed] [Google Scholar]
  107. London S. J., Lehman T. A., Taylor J. A. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997 Nov 15;57(22):5001–5003. [PubMed] [Google Scholar]
  108. London S. J., Sullivan-Klose T., Daly A. K., Idle J. R. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics. 1997 Oct;7(5):401–404. doi: 10.1097/00008571-199710000-00010. [DOI] [PubMed] [Google Scholar]
  109. Mackenzie P. I., Rodbourn L., Iyanagi T. Glucuronidation of carcinogen metabolites by complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases. Cancer Res. 1993 Apr 1;53(7):1529–1533. [PubMed] [Google Scholar]
  110. Mallet W. G., Mosebrook D. R., Trush M. A. Activation of (+-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to diolepoxides by human polymorphonuclear leukocytes or myeloperoxidase. Carcinogenesis. 1991 Mar;12(3):521–524. doi: 10.1093/carcin/12.3.521. [DOI] [PubMed] [Google Scholar]
  111. Marshall R. S., Paterson M. C., Rauth A. M. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis. 1991 Jul;12(7):1175–1180. doi: 10.1093/carcin/12.7.1175. [DOI] [PubMed] [Google Scholar]
  112. Martínez C., Agúndez J. A., Olivera M., Martín R., Ladero J. M., Benítez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics. 1995 Aug;5(4):207–214. [PubMed] [Google Scholar]
  113. Mashimo M., Suzuki T., Abe M., Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet. 1992 Sep-Oct;90(1-2):139–143. doi: 10.1007/BF00210758. [DOI] [PubMed] [Google Scholar]
  114. Masimirembwa C. M., Johansson I., Hasler J. A., Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics. 1993 Dec;3(6):275–280. doi: 10.1097/00008571-199312000-00001. [DOI] [PubMed] [Google Scholar]
  115. Matthias C., Bockmühl U., Jahnke V., Harries L. W., Wolf C. R., Jones P. W., Alldersea J., Worrall S. F., Hand P., Fryer A. A. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics. 1998 Feb;8(1):1–6. doi: 10.1097/00008571-199802000-00001. [DOI] [PubMed] [Google Scholar]
  116. Matthias C., Bockmühl U., Jahnke V., Jones P. W., Hayes J. D., Alldersea J., Gilford J., Bailey L., Bath J., Worrall S. F. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics. 1998 Apr;8(2):91–100. [PubMed] [Google Scholar]
  117. McBride O. W., Umeno M., Gelboin H. V., Gonzalez F. J. A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucleic Acids Res. 1987 Dec 10;15(23):10071–10071. doi: 10.1093/nar/15.23.10071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. McGlynn K. A., Rosvold E. A., Lustbader E. D., Hu Y., Clapper M. L., Zhou T., Wild C. P., Xia X. L., Baffoe-Bonnie A., Ofori-Adjei D. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2384–2387. doi: 10.1073/pnas.92.6.2384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. McLellan R. A., Oscarson M., Seidegård J., Evans D. A., Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 1997 Jun;7(3):187–191. doi: 10.1097/00008571-199706000-00003. [DOI] [PubMed] [Google Scholar]
  120. McWilliams J. E., Sanderson B. J., Harris E. L., Richert-Boe K. E., Henner W. D. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):589–594. [PubMed] [Google Scholar]
  121. Meyer U. A. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):1983–1984. doi: 10.1073/pnas.91.6.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Michejda C. J., Kroeger Koepke M. B. Carcinogen activation by sulfate conjugate formation. Adv Pharmacol. 1994;27:331–363. doi: 10.1016/s1054-3589(08)61038-8. [DOI] [PubMed] [Google Scholar]
  123. Millikan R. C., Pittman G. S., Newman B., Tse C. K., Selmin O., Rockhill B., Savitz D., Moorman P. G., Bell D. A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):371–378. [PubMed] [Google Scholar]
  124. Minchin R. F., Reeves P. T., Teitel C. H., McManus M. E., Mojarrabi B., Ilett K. F., Kadlubar F. F. N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun. 1992 Jun 30;185(3):839–844. doi: 10.1016/0006-291x(92)91703-s. [DOI] [PubMed] [Google Scholar]
  125. Mrozikiewicz P. M., Drakoulis N., Roots I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):626–634. doi: 10.1038/clpt.1994.187. [DOI] [PubMed] [Google Scholar]
  126. Nebert D. W., McKinnon R. A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 1996 Apr;15(4):273–280. doi: 10.1089/dna.1996.15.273. [DOI] [PubMed] [Google Scholar]
  127. Nebert D. W., McKinnon R. A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 1996 Apr;15(4):273–280. doi: 10.1089/dna.1996.15.273. [DOI] [PubMed] [Google Scholar]
  128. Nebert D. W. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. Crit Rev Toxicol. 1989;20(3):153–174. doi: 10.3109/10408448909017908. [DOI] [PubMed] [Google Scholar]
  129. Norppa H., Hirvonen A., Järventaus H., Uusküla M., Tasa G., Ojajärvi A., Sorsa M. Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis. 1995 Jun;16(6):1261–1264. doi: 10.1093/carcin/16.6.1261. [DOI] [PubMed] [Google Scholar]
  130. Nunoya K., Yokoi T., Kimura K., Inoue K., Kodama T., Funayama M., Nagashima K., Funae Y., Green C., Kinoshita M. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics. 1998 Jun;8(3):239–249. doi: 10.1097/00008571-199806000-00006. [DOI] [PubMed] [Google Scholar]
  131. O'Shea D., Davis S. N., Kim R. B., Wilkinson G. R. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther. 1994 Oct;56(4):359–367. doi: 10.1038/clpt.1994.150. [DOI] [PubMed] [Google Scholar]
  132. Oesch F., Glatt H., Schmassmann H. The apparent ubiquity of epoxide hydratase in rat organs. Biochem Pharmacol. 1977 Apr 1;26(7):603–607. doi: 10.1016/0006-2952(77)90032-6. [DOI] [PubMed] [Google Scholar]
  133. Oesch F. Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica. 1973 May;3(5):305–340. doi: 10.3109/00498257309151525. [DOI] [PubMed] [Google Scholar]
  134. Omiecinski C. J., Aicher L., Holubkov R., Checkoway H. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics. 1993 Jun;3(3):150–158. doi: 10.1097/00008571-199306000-00005. [DOI] [PubMed] [Google Scholar]
  135. Owens I. S., Ritter J. K. Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Prog Nucleic Acid Res Mol Biol. 1995;51:305–338. doi: 10.1016/s0079-6603(08)60882-x. [DOI] [PubMed] [Google Scholar]
  136. Pemble S., Schroeder K. R., Spencer S. R., Meyer D. J., Hallier E., Bolt H. M., Ketterer B., Taylor J. B. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J. 1994 May 15;300(Pt 1):271–276. doi: 10.1042/bj3000271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Persson I., Johansson I., Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun. 1997 Feb 3;231(1):227–230. doi: 10.1006/bbrc.1997.6051. [DOI] [PubMed] [Google Scholar]
  138. Persson I., Johansson I., Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun. 1997 Feb 3;231(1):227–230. doi: 10.1006/bbrc.1997.6051. [DOI] [PubMed] [Google Scholar]
  139. Peter R., Böcker R., Beaune P. H., Iwasaki M., Guengerich F. P., Yang C. S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol. 1990 Nov-Dec;3(6):566–573. doi: 10.1021/tx00018a012. [DOI] [PubMed] [Google Scholar]
  140. Phillips I. R., Dolphin C. T., Clair P., Hadley M. R., Hutt A. J., McCombie R. R., Smith R. L., Shephard E. A. The molecular biology of the flavin-containing monooxygenases of man. Chem Biol Interact. 1995 Apr 28;96(1):17–32. doi: 10.1016/0009-2797(94)03580-2. [DOI] [PubMed] [Google Scholar]
  141. Pianezza M. L., Sellers E. M., Tyndale R. F. Nicotine metabolism defect reduces smoking. Nature. 1998 Jun 25;393(6687):750–750. doi: 10.1038/31623. [DOI] [PubMed] [Google Scholar]
  142. Probst-Hensch N. M., Haile R. W., Li D. S., Sakamoto G. T., Louie A. D., Lin B. K., Frankl H. D., Lee E. R., Lin H. J. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis. 1996 Oct;17(10):2125–2129. doi: 10.1093/carcin/17.10.2125. [DOI] [PubMed] [Google Scholar]
  143. Raaka S., Hassett C., Omiencinski C. J. Human microsomal epoxide hydrolase: 5'-flanking region genetic polymorphisms. Carcinogenesis. 1998 Mar;19(3):387–393. doi: 10.1093/carcin/19.3.387. [DOI] [PubMed] [Google Scholar]
  144. Rautio A., Kraul H., Kojo A., Salmela E., Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics. 1992 Oct;2(5):227–233. doi: 10.1097/00008571-199210000-00005. [DOI] [PubMed] [Google Scholar]
  145. Rettie A. E., Wienkers L. C., Gonzalez F. J., Trager W. F., Korzekwa K. R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 Feb;4(1):39–42. doi: 10.1097/00008571-199402000-00005. [DOI] [PubMed] [Google Scholar]
  146. Risch A., Wallace D. M., Bathers S., Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet. 1995 Feb;4(2):231–236. doi: 10.1093/hmg/4.2.231. [DOI] [PubMed] [Google Scholar]
  147. Rojas M., Camus A. M., Alexandrov K., Husgafvel-Pursiainen K., Anttila S., Vainio H., Bartsch H. Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. Carcinogenesis. 1992 Jun;13(6):929–933. doi: 10.1093/carcin/13.6.929. [DOI] [PubMed] [Google Scholar]
  148. Rostami-Hodjegan A., Lennard M. S., Woods H. F., Tucker G. T. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics. 1998 Jun;8(3):227–238. doi: 10.1097/00008571-199806000-00005. [DOI] [PubMed] [Google Scholar]
  149. Rosvold E. A., McGlynn K. A., Lustbader E. D., Buetow K. H. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 1995 Aug;5(4):199–206. doi: 10.1097/00008571-199508000-00003. [DOI] [PubMed] [Google Scholar]
  150. Rothman N., Hayes R. B., Bi W., Caporaso N., Broly F., Woosley R. L., Yin S., Feng P., You X., Meyer U. A. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics. 1993 Oct;3(5):250–255. doi: 10.1097/00008571-199310000-00004. [DOI] [PubMed] [Google Scholar]
  151. Ryberg D., Skaug V., Hewer A., Phillips D. H., Harries L. W., Wolf C. R., Ogreid D., Ulvik A., Vu P., Haugen A. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 1997 Jul;18(7):1285–1289. doi: 10.1093/carcin/18.7.1285. [DOI] [PubMed] [Google Scholar]
  152. Saarikoski S. T., Voho A., Reinikainen M., Anttila S., Karjalainen A., Malaveille C., Vainio H., Husgafvel-Pursiainen K., Hirvonen A. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer. 1998 Aug 12;77(4):516–521. doi: 10.1002/(sici)1097-0215(19980812)77:4<516::aid-ijc7>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  153. Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997 Feb;60(2):284–295. [PMC free article] [PubMed] [Google Scholar]
  154. Schmekel B., Hörnblad Y., Linden M., Sundström C., Venge P. Myeloperoxidase in human lung lavage. II. Internalization of myeloperoxidase by alveolar macrophages. Inflammation. 1990 Aug;14(4):455–461. doi: 10.1007/BF00914096. [DOI] [PubMed] [Google Scholar]
  155. Schmekel B., Karlsson S. E., Linden M., Sundström C., Tegner H., Venge P. Myeloperoxidase in human lung lavage. I. A marker of local neutrophil activity. Inflammation. 1990 Aug;14(4):447–454. doi: 10.1007/BF00914095. [DOI] [PubMed] [Google Scholar]
  156. Schröder K. R., Hallier E., Peter H., Bolt H. M. Dissociation of a new glutathione S-transferase activity in human erythrocytes. Biochem Pharmacol. 1992 Apr 15;43(8):1671–1674. doi: 10.1016/0006-2952(92)90695-f. [DOI] [PubMed] [Google Scholar]
  157. Schulz W. A., Krummeck A., Rösinger I., Eickelmann P., Neuhaus C., Ebert T., Schmitz-Dräger B. J., Sies H. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997 Jun;7(3):235–239. doi: 10.1097/00008571-199706000-00008. [DOI] [PubMed] [Google Scholar]
  158. Seidegård J., Ekström G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect. 1997 Jun;105 (Suppl 4):791–799. doi: 10.1289/ehp.105-1470052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Seidegård J., Vorachek W. R., Pero R. W., Pearson W. R. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7293–7297. doi: 10.1073/pnas.85.19.7293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Shields P. G., Sugimura H., Caporaso N. E., Petruzzelli S. F., Bowman E. D., Trump B. F., Weston A., Harris C. C. Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism. Environ Health Perspect. 1992 Nov;98:191–194. doi: 10.1289/ehp.9298191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994 Jul;270(1):414–423. [PubMed] [Google Scholar]
  162. Shou M., Krausz K. W., Gonzalez F. J., Gelboin H. V. Metabolic activation of the potent carcinogen dibenzo[a,l]pyrene by human recombinant cytochromes P450, lung and liver microsomes. Carcinogenesis. 1996 Nov;17(11):2429–2433. doi: 10.1093/carcin/17.11.2429. [DOI] [PubMed] [Google Scholar]
  163. Sims P., Grover P. L., Swaisland A., Pal K., Hewer A. Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. Nature. 1974 Nov 22;252(5481):326–328. doi: 10.1038/252326a0. [DOI] [PubMed] [Google Scholar]
  164. Smith C. A., Harrison D. J. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997 Aug 30;350(9078):630–633. doi: 10.1016/S0140-6736(96)08061-0. [DOI] [PubMed] [Google Scholar]
  165. Smith G., Stanley L. A., Sim E., Strange R. C., Wolf C. R. Metabolic polymorphisms and cancer susceptibility. Cancer Surv. 1995;25:27–65. [PubMed] [Google Scholar]
  166. Sugimura H., Wakai K., Genka K., Nagura K., Igarashi H., Nagayama K., Ohkawa A., Baba S., Morris B. J., Tsugane S. Association of Ile462Val (Exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):413–417. [PubMed] [Google Scholar]
  167. Sugimura T. Multistep carcinogenesis: a 1992 perspective. Science. 1992 Oct 23;258(5082):603–607. doi: 10.1126/science.1411570. [DOI] [PubMed] [Google Scholar]
  168. Swanson H. I., Bradfield C. A. The AH-receptor: genetics, structure and function. Pharmacogenetics. 1993 Oct;3(5):213–230. doi: 10.1097/00008571-199310000-00001. [DOI] [PubMed] [Google Scholar]
  169. Swanson H. I., Bradfield C. A. The AH-receptor: genetics, structure and function. Pharmacogenetics. 1993 Oct;3(5):213–230. doi: 10.1097/00008571-199310000-00001. [DOI] [PubMed] [Google Scholar]
  170. Taylor J. A., Umbach D. M., Stephens E., Castranio T., Paulson D., Robertson C., Mohler J. L., Bell D. A. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res. 1998 Aug 15;58(16):3603–3610. [PubMed] [Google Scholar]
  171. Tefre T., Ryberg D., Haugen A., Nebert D. W., Skaug V., Brøgger A., Børresen A. L. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics. 1991 Oct;1(1):20–25. doi: 10.1097/00008571-199110000-00004. [DOI] [PubMed] [Google Scholar]
  172. To-Figueras J., Gené M., Gómez-Catalán J., Galán M. C., Fuentes M., Ramón J. M., Rodamilans M., Huguet E., Corbella J. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among Northwestern Mediterraneans. Carcinogenesis. 1997 Aug;18(8):1529–1533. doi: 10.1093/carcin/18.8.1529. [DOI] [PubMed] [Google Scholar]
  173. Traver R. D., Horikoshi T., Danenberg K. D., Stadlbauer T. H., Danenberg P. V., Ross D., Gibson N. W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992 Feb 15;52(4):797–802. [PubMed] [Google Scholar]
  174. Turesky R. J., Lang N. P., Butler M. A., Teitel C. H., Kadlubar F. F. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis. 1991 Oct;12(10):1839–1845. doi: 10.1093/carcin/12.10.1839. [DOI] [PubMed] [Google Scholar]
  175. Uematsu F., Ikawa S., Kikuchi H., Sagami I., Kanamaru R., Abe T., Satoh K., Motomiya M., Watanabe M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics. 1994 Apr;4(2):58–63. doi: 10.1097/00008571-199404000-00002. [DOI] [PubMed] [Google Scholar]
  176. Uematsu F., Kikuchi H., Abe T., Motomiya M., Ohmachi T., Sagami I., Watanabe M. MspI polymorphism of the human CYP2E gene. Nucleic Acids Res. 1991 Oct 25;19(20):5797–5797. doi: 10.1093/nar/19.20.5797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  177. Uematsu F., Kikuchi H., Motomiya M., Abe T., Ishioka C., Kanamaru R., Sagami I., Watanabe M. Human cytochrome P450IIE1 gene: DraI polymorphism and susceptibility to cancer. Tohoku J Exp Med. 1992 Oct;168(2):113–117. doi: 10.1620/tjem.168.113. [DOI] [PubMed] [Google Scholar]
  178. Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., Wakui A., Kanamaru R., Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res. 1991 Mar;82(3):254–256. doi: 10.1111/j.1349-7006.1991.tb01838.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Uematsu F., Kikuchi H., Ohmachi T., Sagami I., Motomiya M., Kamataki T., Komori M., Watanabe M. Two common RFLPs of the human CYP2E gene. Nucleic Acids Res. 1991 May 25;19(10):2803–2803. doi: 10.1093/nar/19.10.2803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  180. Vatsis K. P., Weber W. W., Bell D. A., Dupret J. M., Evans D. A., Grant D. M., Hein D. W., Lin H. J., Meyer U. A., Relling M. V. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995 Feb;5(1):1–17. doi: 10.1097/00008571-199502000-00001. [DOI] [PubMed] [Google Scholar]
  181. Vatsis K. P., Weber W. W. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys. 1993 Feb 15;301(1):71–76. doi: 10.1006/abbi.1993.1116. [DOI] [PubMed] [Google Scholar]
  182. Vesell E. S., Seaton T. D., A-Rahim Y. I. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics. 1995 Feb;5(1):53–57. doi: 10.1097/00008571-199502000-00007. [DOI] [PubMed] [Google Scholar]
  183. Vogelstein B., Kinzler K. W. The multistep nature of cancer. Trends Genet. 1993 Apr;9(4):138–141. doi: 10.1016/0168-9525(93)90209-z. [DOI] [PubMed] [Google Scholar]
  184. Watanabe J., Hayashi S., Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5'-flanking region. J Biochem. 1994 Aug;116(2):321–326. doi: 10.1093/oxfordjournals.jbchem.a124526. [DOI] [PubMed] [Google Scholar]
  185. Wiencke J. K., Pemble S., Ketterer B., Kelsey K. T. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):253–259. [PubMed] [Google Scholar]
  186. Wild D., Feser W., Michel S., Lord H. L., Josephy P. D. Metabolic activation of heterocyclic aromatic amines catalyzed by human arylamine N-acetyltransferase isozymes (NAT1 and NAT2) expressed in Salmonella typhimurium. Carcinogenesis. 1995 Mar;16(3):643–648. doi: 10.1093/carcin/16.3.643. [DOI] [PubMed] [Google Scholar]
  187. Xu X., Kelsey K. T., Wiencke J. K., Wain J. C., Christiani D. C. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1996 Sep;5(9):687–692. [PubMed] [Google Scholar]
  188. Yanagawa Y., Sawada M., Deguchi T., Gonzalez F. J., Kamataki T. Stable expression of human CYP1A2 and N-acetyltransferases in Chinese hamster CHL cells: mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. Cancer Res. 1994 Jul 1;54(13):3422–3427. [PubMed] [Google Scholar]
  189. Yengi L., Inskip A., Gilford J., Alldersea J., Bailey L., Smith A., Lear J. T., Heagerty A. H., Bowers B., Hand P. Polymorphism at the glutathione S-transferase locus GSTM3: interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res. 1996 May 1;56(9):1974–1977. [PubMed] [Google Scholar]
  190. Yokoi T., Sawada M., Kamataki T. Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics. 1995;5(Spec No):S65–S69. doi: 10.1097/00008571-199512001-00003. [DOI] [PubMed] [Google Scholar]
  191. Zenser T. V., Lakshmi V. M., Rustan T. D., Doll M. A., Deitz A. C., Davis B. B., Hein D. W. Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res. 1996 Sep 1;56(17):3941–3947. [PubMed] [Google Scholar]
  192. Zimniak P., Nanduri B., Pikuła S., Bandorowicz-Pikuła J., Singhal S. S., Srivastava S. K., Awasthi S., Awasthi Y. C. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 1994 Sep 15;224(3):893–899. doi: 10.1111/j.1432-1033.1994.00893.x. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES